The UK’s cell and gene therapy sector is on the threshold of becoming a global leader in the field. While present challenges include the supply of equipment and skills gaps, Innovation Hubs aim to bridge these through collaboration.
Given the widespread incidence of cancers and cardiovascular diseases, having sufficient means to model their behaviour is vital to the development of new treatments. Maintaining tissue contexts in disease modelling is crucial for developing a comprehensive understanding of how different diseases behave.
3D cell modelling can help develop understandings of disease pathologies, facilitating the investigation of how tissues react to certain treatments without causing undue harm or risk to the patients who need them.
With a host of factors to consider in cell and gene manufacture, upscaling is still no small task. However, as industry experience accumulates and new technologies arrive on the market, there are an increasing number of options for developers looking to get their therapeutic on the road to the clinic.
Regulatory approval is, as ever, a crucial factor to bear in mind during the later phases of clinical trials. Regardless of the cell line approach chosen, keeping a consistent process and product output is key for establishing a successful project without it being hamstrung at the final hurdle.
The lack of predictive models is a highly limiting factor in the efficacy of projects designed to find new therapeutic targets. Cutting-edge organoid models may be the key to overcoming these challenges and could improve the prediction candidate drug molecules' clinical success.
Hemant Dhamne, Head of Process Development of Gene Therapy at King's College London, discusses the process of viral vector production, the current and future manufacturing technologies, and challenges in the field.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.